Hydroxyprogesterone Caproate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Hydroxyprogesterone Caproate
- Hydroxyprogesterone Caproate: From Preterm Birth Prevention to Endometriosis of Uterus
Hydroxyprogesterone Caproate: From Preterm Birth Prevention to Endometriosis of Uterus
One-Sentence Summary
Hydroxyprogesterone caproate (17-OHPC) is a synthetic progestogen primarily known internationally for its use in the prevention of preterm birth in high-risk pregnancies, with a long history of use in hormonal management of gynaecological conditions including endometrial cancer. The TxGNN model predicts it may be effective for Endometriosis of Uterus, with no clinical trials and only 2 peripheral publications providing indirect contextual support for this direction. Given the absence of direct clinical evidence and the drug's non-registered status in Singapore, this candidate requires further mechanistic validation and literature review before it can be advanced.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in Singapore; internationally known use: preterm birth prevention / progestogenic therapy |
| Predicted New Indication | Endometriosis of Uterus |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only; no direct clinical studies on this indication) |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this dataset. Based on established pharmacology, hydroxyprogesterone caproate is a synthetic ester of 17α-hydroxyprogesterone — a naturally occurring progestogen. It acts primarily through progesterone receptors, suppressing gonadotropin secretion, reducing estrogen-driven proliferation of endometrial tissue, and modulating the hormonal environment of the uterus. This hormonal profile forms the mechanistic bridge between the drug and oestrogen-dependent reproductive conditions.
Endometriosis of the uterus (which encompasses adenomyosis and uterine endometriosis) is fundamentally an oestrogen-dependent, progesterone-resistant condition. Progestogens are a cornerstone class of medical treatment for endometriosis, acting to oppose oestrogen-driven proliferation and induce decidualisation or atrophy of ectopic endometrial implants. The TxGNN score of 99.98% likely reflects the strong mechanistic alignment between progestogenic pharmacology and the hormone-driven pathophysiology of endometriosis, captured through patterns in the knowledge graph.
Importantly, this drug has a substantial body of historical evidence in closely related gynecological conditions — uterine corpus cancer (rank 6, 9 publications) and endometrial cancer (rank 8, 20 publications and 1 clinical trial) — documenting its hormonal effects on uterine and endometrial tissue dating back to the 1960s. This cross-indication evidence reinforces the biological plausibility of the TxGNN prediction and suggests that the progestogenic mechanism may be applicable to benign hormone-dependent conditions such as endometriosis.
Clinical Trial Evidence
Currently no related clinical trials registered for hydroxyprogesterone caproate in endometriosis of the uterus.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37488914 | 2023 | Case Report | The American Journal of Case Reports | 41-year-old woman with adenomyosis developed spontaneous hemoperitoneum due to endometriosis at 28 weeks of pregnancy; highlights endometriosis as a major risk factor and illustrates the severity of hormone-dependent uterine disease |
| 3158227 | 1985 | Clinical Study | Akusherstvo i Ginekologiia | Describes structural changes in pathologically altered uterine tissue following sex hormone treatment; provides indirect evidence for hormonal modulation of uterine pathology |
Note: Neither publication directly evaluates hydroxyprogesterone caproate as a therapeutic intervention for endometriosis. Both are cited as peripherally relevant contextual evidence only.
Singapore Market Information
Hydroxyprogesterone caproate is not registered in Singapore. No licensed products are currently available on the local market.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Direct clinical evidence supporting hydroxyprogesterone caproate for endometriosis of the uterus is absent (L5 evidence level), with only two peripheral publications and no registered clinical trials. The drug is also not currently marketed in Singapore, and both mechanism of action and safety data are unavailable in the current dataset, making a robust risk-benefit assessment impossible at this stage.
To proceed, the following is needed:
- Retrieve complete MOA and pharmacodynamic data from DrugBank (DB06789) to formally characterise the progestogenic mechanism
- Obtain and review the full package insert (or equivalent prescribing information) for warnings, contraindications, and drug interaction profile
- Conduct a dedicated systematic literature review of progestogens — including 17-OHPC specifically — for endometriosis treatment to determine whether class-level evidence can be applied
- Cross-reference the substantially stronger evidence base for the related indication of endometrial cancer (rank 8: 20 publications, 1 clinical trial) to build the mechanistic argument for indication expansion
- Assess the regulatory pathway for Singapore registration, including feasibility of a new drug application or compassionate use framework given the current non-marketed status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.